HK1116777A1 - Improved cytotoxic agents comprising new maytansinoids - Google Patents
Improved cytotoxic agents comprising new maytansinoidsInfo
- Publication number
- HK1116777A1 HK1116777A1 HK08107275.3A HK08107275A HK1116777A1 HK 1116777 A1 HK1116777 A1 HK 1116777A1 HK 08107275 A HK08107275 A HK 08107275A HK 1116777 A1 HK1116777 A1 HK 1116777A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cytotoxic agents
- improved cytotoxic
- new maytansinoids
- maytansinoids
- new
- Prior art date
Links
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 239000002254 cytotoxic agent Substances 0.000 title 1
- 231100000599 cytotoxic agent Toxicity 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47173903P | 2003-05-20 | 2003-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1116777A1 true HK1116777A1 (en) | 2009-01-02 |
Family
ID=33476883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08107275.3A HK1116777A1 (en) | 2003-05-20 | 2008-07-02 | Improved cytotoxic agents comprising new maytansinoids |
Country Status (28)
Country | Link |
---|---|
EP (4) | EP3031810B1 (fr) |
JP (2) | JP5208420B2 (fr) |
KR (1) | KR101145506B1 (fr) |
CN (2) | CN1956722A (fr) |
AU (1) | AU2004240541B2 (fr) |
BR (2) | BRPI0410748B8 (fr) |
CA (1) | CA2525130C (fr) |
CL (1) | CL2012000651A1 (fr) |
CO (1) | CO5660276A2 (fr) |
CR (1) | CR20170291A (fr) |
CY (2) | CY1117161T1 (fr) |
DK (2) | DK1651162T3 (fr) |
EA (1) | EA010909B1 (fr) |
EC (1) | ECSP056149A (fr) |
ES (2) | ES2559670T3 (fr) |
HK (1) | HK1116777A1 (fr) |
HR (2) | HRP20160046T1 (fr) |
HU (2) | HUE028314T2 (fr) |
IL (6) | IL171170A (fr) |
LT (1) | LT3524611T (fr) |
MX (3) | MX340862B (fr) |
NO (1) | NO339597B1 (fr) |
NZ (1) | NZ542695A (fr) |
PL (2) | PL3524611T3 (fr) |
PT (2) | PT1651162E (fr) |
SI (2) | SI1651162T1 (fr) |
WO (1) | WO2004103272A2 (fr) |
ZA (1) | ZA200507845B (fr) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1651162T1 (sl) * | 2003-05-20 | 2016-02-29 | Immunogen, Inc. | Izboljšani citotoksični agenti, ki vsebujejo nove majtanzinoide |
PL1819359T3 (pl) | 2004-12-09 | 2015-08-31 | Janssen Biotech Inc | Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie |
US20060182750A1 (en) * | 2005-02-11 | 2006-08-17 | Immunogen, Inc. | Process for preparing stable drug conjugates |
CA2604885A1 (fr) | 2005-04-07 | 2006-10-19 | Guoying Yu | Cacna1e dans le diagnostic, la detection et le traitement du cancer |
US20090220495A1 (en) | 2005-04-07 | 2009-09-03 | Abdallah Fanidi | Cancer Related Genes (PRLR) |
EA200702239A1 (ru) | 2005-04-15 | 2008-10-30 | Иммьюноджен, Инк. | Уничтожение гетерогенной или смешанной клеточной популяции в опухолях |
CA2620343C (fr) * | 2005-08-24 | 2013-01-08 | Immunogen, Inc. | Procede de preparation de conjugues maytansinoides-anticorps |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
ES2374964T3 (es) | 2006-01-25 | 2012-02-23 | Sanofi | Agentes citotóxicos que comprenden nuevos derivados de tomaimicina. |
EP2389951A1 (fr) | 2006-03-23 | 2011-11-30 | Novartis AG | Thérapeutique anticorps antigène de cellules anti-tumorales |
EP2012827A2 (fr) | 2006-04-13 | 2009-01-14 | Novartis Vaccines and Diagnostics, Inc. | Procede de traitement, de diagnostic ou de detection du cancer |
EP2125898B1 (fr) | 2007-03-14 | 2013-05-15 | Novartis AG | Utilisation d'inhibiteurs du gène apcdd1 pour traiter, diagnostiquer ou détecter le cancer |
KR20100137585A (ko) | 2008-04-30 | 2010-12-30 | 이뮤노젠 아이엔씨 | 강력한 복합체 및 친수성 링커 |
TR201907573T4 (tr) * | 2009-06-03 | 2019-06-21 | Immunogen Inc | Konjugasyon yöntemleri̇ |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
UY32913A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero |
CN102596922A (zh) * | 2009-10-06 | 2012-07-18 | 免疫基因公司 | 有效的缀合物和亲水性连接体 |
WO2011045396A2 (fr) | 2009-10-16 | 2011-04-21 | Novartis Ag | Biomarqueurs de réponse pharmacodynamique de tumeur |
FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
WO2012016227A2 (fr) | 2010-07-29 | 2012-02-02 | Xencor, Inc. | Anticorps dont les points isoélectriques sont modifiés |
EP3828205A1 (fr) | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anticorps anti-ror1 |
CA2816681A1 (fr) * | 2010-11-03 | 2012-05-10 | Immunogen, Inc. | Agents cytotoxiques comprenant de nouveaux derives d'ansamitocine |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
RU2451010C1 (ru) * | 2011-01-11 | 2012-05-20 | Закрытое Акционерное Общество "Ива Фарм" | Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия |
RS58367B1 (sr) | 2011-03-29 | 2019-03-29 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
EP2524929A1 (fr) * | 2011-05-17 | 2012-11-21 | Sanofi | Utilisation d'anticorps immunoconjugués anti-CD19 maytansinoïdes pour le traitement de symptômes de malignités CD19+lymphocytes B |
EP2550975A1 (fr) * | 2011-07-29 | 2013-01-30 | Sanofi | Polythérapie pour le traitement de symptômes de malignités CD19+lymphocytes B comprenant un immunoconjugué anti-CD19 maytansinoïde et du rituximab |
EP2766392B1 (fr) | 2011-10-10 | 2019-07-17 | Xencor, Inc. | Méthode de purification d'anticorps |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
PL3486248T3 (pl) * | 2012-09-26 | 2021-10-25 | Immunogen, Inc. | Ulepszone sposoby acylacji majtansynolu |
RU2018122734A (ru) | 2012-10-04 | 2018-07-24 | Иммуноджен, Инк. | Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент-цитотоксический агент |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
EP2943511B1 (fr) | 2013-01-14 | 2019-08-07 | Xencor, Inc. | Nouvelles protéines hétérodimères |
WO2014113510A1 (fr) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Elimination rapide de complexes antigéniques à l'aide de nouveaux anticorps |
CN103933575B (zh) | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
WO2014145907A1 (fr) | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Ciblage des lymphocytes t avec des protéines hétérodimères |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
ES2885696T3 (es) | 2013-03-15 | 2021-12-15 | Xencor Inc | Proteínas heterodiméricas |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd38及びcd3に結合する二重特異性抗体 |
CN104974252B (zh) * | 2014-04-01 | 2020-04-24 | 三生国健药业(上海)股份有限公司 | 一种抑制肿瘤生长的抗体-小分子药物偶联物及其制备方法和用途 |
CA2953371C (fr) * | 2014-06-30 | 2021-08-24 | Tarveda Therapeutics, Inc. | Conjugues cibles, particules et preparations associees |
WO2016014984A1 (fr) | 2014-07-24 | 2016-01-28 | Xencor, Inc. | Élimination rapide de complexes antigéniques à l'aide de nouveaux anticorps |
SG11201701328XA (en) | 2014-09-02 | 2017-03-30 | Immunogen Inc | Methods for formulating antibody drug conjugate compositions |
TWI697493B (zh) | 2014-09-03 | 2020-07-01 | 美商免疫原公司 | 細胞毒性苯并二氮呯衍生物 |
TW201613930A (en) | 2014-09-03 | 2016-04-16 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
EP3223845B1 (fr) | 2014-11-26 | 2021-05-19 | Xencor, Inc. | Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20 |
MA41019A (fr) | 2014-11-26 | 2021-05-05 | Xencor Inc | Anticorps hétérodimériques se liant aux antigènes cd3 et cd38 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
EP3237449A2 (fr) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Anticorps trispécifiques |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
CN106279352B (zh) | 2015-05-29 | 2020-05-22 | 上海新理念生物医药科技有限公司 | 海兔毒素10的衍生物及其应用 |
EP3308801A4 (fr) | 2015-06-09 | 2019-02-27 | XDCExplorer (Shanghai) Co., Ltd. | Conjugué anticorps-médicament, intermédiaire, procédé de préparation, compositions pharmaceutique et leurs utilisations |
EP3368546A4 (fr) | 2015-10-28 | 2019-06-26 | Tarveda Therapeutics, Inc. | Conjugués ciblés sstr, et ses particules et formulations |
CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
CA3007030A1 (fr) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Anticorps heterodimees se liant a cd3 et psma |
RU2022104399A (ru) | 2016-06-14 | 2022-05-05 | Ксенкор, Инк. | Биспецифические антитела-ингибиторы контрольных точек |
CN116063545A (zh) | 2016-06-28 | 2023-05-05 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
GB201615725D0 (en) | 2016-09-15 | 2016-11-02 | Polytherics Ltd | Novel cytotoxic agents and conjugates thereof |
KR102649972B1 (ko) | 2016-10-14 | 2024-03-22 | 젠코어 인코포레이티드 | IL15/IL15Rα 이종이량체 Fc-융합 단백질 |
JP2019535829A (ja) | 2016-11-21 | 2019-12-12 | エイリオン セラピューティクス, インコーポレイテッド | 大型薬剤の経皮送達 |
IL298414A (en) | 2017-02-28 | 2023-01-01 | Immunogen Inc | History of methanosinoids with peptide linkers and their conjugates |
GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
WO2018195243A1 (fr) | 2017-04-20 | 2018-10-25 | Immunogen, Inc. | Dérivés de benzodiazépine cytotoxiques et leurs conjugués |
CA3067603A1 (fr) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | Proteines de fusion fc heterodimeres ciblees contenant il-15/il-15ra et domaines de liaison a l'antigene |
AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
WO2019105835A1 (fr) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinaisons de copanlisib et d'anetumab ravtansine |
CA3086199A1 (fr) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Proteines de fusion il-2 fc modifiees |
EP3732178A1 (fr) | 2017-12-28 | 2020-11-04 | ImmunoGen, Inc. | Dérivés de benzodiazépine |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
CA3097741A1 (fr) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Proteines de fusion heterodimeres ciblant tim-3 contenant des proteines de fusion fc d'il-15/il-15ra et domaines de liaison a l'antigene de tim-3 |
EP3781599A1 (fr) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Protéines de fusion hétérodimères ciblant pd-1 contenant des protéines de fusion fc d'il-15/il-15ra, domaines de liaison à l'antigène pd-1 et utilisations associées |
GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
WO2020010079A2 (fr) | 2018-07-02 | 2020-01-09 | Amgen Inc. | Protéine de liaison à l'antigène anti-steap1 |
WO2020023871A1 (fr) | 2018-07-27 | 2020-01-30 | Promega Corporation | Conjugués contenant de la quinone |
WO2020072821A2 (fr) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Protéines de fusion fc hétérodimères d'il -12 |
MX2021010390A (es) | 2019-03-01 | 2021-11-17 | Xencor Inc | Anticuerpos heterodimericos que se unen a enpp3 y cd3. |
EP3956332B1 (fr) * | 2019-04-18 | 2023-02-22 | Indena S.p.A. | Procédé diastéréosélectif pour la préparation d'esters de maytansinoides contenant du thiol ou du disulfure et intermédiaires correspondants |
WO2020234114A1 (fr) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | Nouvelle formulation stable à haute concentration pour anetumab ravtansine |
CN114302744A (zh) | 2019-07-10 | 2022-04-08 | 赛博克萨3公司 | 作为治疗剂的微管靶向剂的肽缀合物 |
PE20220563A1 (es) | 2019-07-10 | 2022-04-13 | Cybrexa 2 Inc | Conjugados peptidicos de citotoxinas como terapeuticos |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
AU2021329378A1 (en) | 2020-08-19 | 2023-03-23 | Xencor, Inc. | Anti-CD28 compositions |
AU2022232375A1 (en) | 2021-03-09 | 2023-09-21 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
WO2023089314A1 (fr) | 2021-11-18 | 2023-05-25 | Oxford Biotherapeutics Limited | Combinaisons pharmaceutiques |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (fr) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotique C-15003 PHO et sa préparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (fr) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | Composes 4,5-deoxymaytansinoide et leur procede de preparation |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (fr) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
SE9102074D0 (sv) | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
WO1999006587A2 (fr) | 1997-08-01 | 1999-02-11 | Morphosys Ag | Nouvelle methode et nouveau phage d'identification d'une sequence d'acide nucleique |
EP2289549A3 (fr) * | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Des immunoconjugués pour le traitement des cancers. |
US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
EP1258255A1 (fr) * | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugués d'un anticorps contre CD44 et d'un maytansinoide |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
ATE506965T1 (de) * | 2001-09-05 | 2011-05-15 | Genentech Inc | Verfahren zur identifikation von polypeptid- antigenen im zusammenhang mit störungen durch aberrante zellproliferation |
CN102940889A (zh) * | 2003-05-14 | 2013-02-27 | 伊缪诺金公司 | 药物缀合物组合物 |
SI1651162T1 (sl) * | 2003-05-20 | 2016-02-29 | Immunogen, Inc. | Izboljšani citotoksični agenti, ki vsebujejo nove majtanzinoide |
EA014640B1 (ru) * | 2003-07-21 | 2010-12-30 | Иммьюноджен, Инк. | Антитело или его эпитоп-связывающий фрагмент, которые связываются с гликотопом са6, и способы их применения |
-
2004
- 2004-05-20 SI SI200432295T patent/SI1651162T1/sl unknown
- 2004-05-20 NZ NZ542695A patent/NZ542695A/en unknown
- 2004-05-20 HU HUE04750945A patent/HUE028314T2/en unknown
- 2004-05-20 HU HUE19160750A patent/HUE054074T2/hu unknown
- 2004-05-20 MX MX2013008224A patent/MX340862B/es unknown
- 2004-05-20 WO PCT/US2004/013314 patent/WO2004103272A2/fr active Application Filing
- 2004-05-20 PL PL19160750T patent/PL3524611T3/pl unknown
- 2004-05-20 PL PL04750945T patent/PL1651162T3/pl unknown
- 2004-05-20 CN CNA2004800134886A patent/CN1956722A/zh active Pending
- 2004-05-20 JP JP2006532511A patent/JP5208420B2/ja not_active Expired - Lifetime
- 2004-05-20 SI SI200432508T patent/SI3524611T1/sl unknown
- 2004-05-20 CN CN200710194150.0A patent/CN101186613B/zh not_active Expired - Lifetime
- 2004-05-20 CA CA2525130A patent/CA2525130C/fr not_active Expired - Lifetime
- 2004-05-20 EA EA200501836A patent/EA010909B1/ru unknown
- 2004-05-20 LT LTEP19160750.6T patent/LT3524611T/lt unknown
- 2004-05-20 DK DK04750945.0T patent/DK1651162T3/en active
- 2004-05-20 EP EP15190436.4A patent/EP3031810B1/fr not_active Expired - Lifetime
- 2004-05-20 CR CR20170291A patent/CR20170291A/es unknown
- 2004-05-20 BR BRPI0410748A patent/BRPI0410748B8/pt active IP Right Grant
- 2004-05-20 BR BRPI0419348A patent/BRPI0419348B8/pt active IP Right Grant
- 2004-05-20 EP EP19160750.6A patent/EP3524611B1/fr not_active Expired - Lifetime
- 2004-05-20 DK DK19160750.6T patent/DK3524611T3/da active
- 2004-05-20 EP EP20216572.6A patent/EP3851126A1/fr active Pending
- 2004-05-20 ES ES04750945.0T patent/ES2559670T3/es not_active Expired - Lifetime
- 2004-05-20 PT PT47509450T patent/PT1651162E/pt unknown
- 2004-05-20 AU AU2004240541A patent/AU2004240541B2/en not_active Expired
- 2004-05-20 ES ES19160750T patent/ES2863498T3/es not_active Expired - Lifetime
- 2004-05-20 EP EP04750945.0A patent/EP1651162B1/fr not_active Expired - Lifetime
- 2004-05-20 MX MXPA05011811A patent/MXPA05011811A/es active IP Right Grant
- 2004-05-20 MX MX2016009879A patent/MX370281B/es unknown
- 2004-05-20 PT PT191607506T patent/PT3524611T/pt unknown
- 2004-05-20 KR KR1020057022166A patent/KR101145506B1/ko active IP Right Grant
-
2005
- 2005-09-28 ZA ZA200507845A patent/ZA200507845B/en unknown
- 2005-09-29 IL IL171170A patent/IL171170A/en active IP Right Grant
- 2005-11-03 CO CO05112351A patent/CO5660276A2/es unknown
- 2005-11-10 EC EC2005006149A patent/ECSP056149A/es unknown
- 2005-12-19 NO NO20056039A patent/NO339597B1/no unknown
-
2008
- 2008-07-02 HK HK08107275.3A patent/HK1116777A1/xx not_active IP Right Cessation
-
2011
- 2011-06-30 IL IL213876A patent/IL213876A/en active IP Right Grant
-
2012
- 2012-03-14 CL CL2012000651A patent/CL2012000651A1/es unknown
- 2012-11-27 IL IL223297A patent/IL223297A/en active IP Right Grant
-
2013
- 2013-01-04 JP JP2013000052A patent/JP5563673B2/ja not_active Expired - Lifetime
-
2014
- 2014-03-30 IL IL231810A patent/IL231810A/en active IP Right Grant
-
2015
- 2015-05-19 IL IL238894A patent/IL238894A/en active IP Right Grant
- 2015-09-06 IL IL241211A patent/IL241211B/en active IP Right Grant
-
2016
- 2016-01-14 HR HRP20160046TT patent/HRP20160046T1/hr unknown
- 2016-01-21 CY CY20161100067T patent/CY1117161T1/el unknown
-
2021
- 2021-03-19 HR HRP20210464TT patent/HRP20210464T1/hr unknown
- 2021-03-26 CY CY20211100265T patent/CY1124278T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1116777A1 (en) | Improved cytotoxic agents comprising new maytansinoids | |
GB0303910D0 (en) | Therapeutic agents | |
EP1614386A4 (fr) | Appareil d'echographie | |
EP1665987A4 (fr) | Echographe | |
EP1638612A4 (fr) | Agents d'imagerie a cible de cox-2 | |
EP1676582A4 (fr) | Agent luttant contre le coronavirus | |
GB0315259D0 (en) | Use | |
GB0305989D0 (en) | Agent | |
GB0303683D0 (en) | Antimicrobial agents | |
GB0301350D0 (en) | Therapeutic agents | |
GB0302741D0 (en) | Use | |
GB0316889D0 (en) | Pharmaceutical agents | |
GB0313511D0 (en) | Combination | |
EP1709976A4 (fr) | Inducteur emt | |
GB0423316D0 (en) | Opthalmoscope | |
GB0316757D0 (en) | Use | |
IL164811A0 (en) | Vitamin-targeted inaging agents | |
GB0303623D0 (en) | Muscarinic agents | |
GB0306445D0 (en) | Conjugate | |
GB0316208D0 (en) | New cytotoxic steriod compounds | |
GB0323861D0 (en) | Use | |
GB0325977D0 (en) | Use | |
GB0310754D0 (en) | Use | |
GB0325976D0 (en) | Use | |
GB0310755D0 (en) | Use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20240519 |